降血壓及降血脂藥物對慢性腎臟疾病的影響

The effect of Anti-hypertensive drugs and Anti-hyperlipidemic drugs for chronic kidney disease

陳瑩真(Ying-Chen Chen)

指導教授 ： 楊淑惠 ； 龍嘉麒 ； 廖勇柏

中山醫學大學/健康管理學院/公共衛生學系碩士班/碩士(2012年)

https://doi.org/10.6834/CSMU.2012.00025

摘要

研究目的：本研究探討老年人，在使用率較高之降血壓及降血脂藥物後,對於慢性腎臟疾病所造成的影響。
研究方法：採回溯性(retrospective)的世代追蹤研究法，資料來源是利用全民健保資料庫(National Health Insurance Research Database，NHIRD)三十二萬筆資料，分析研究對象為老年人(年齡>60)於2000~2009年間，比較慢性腎臟疾病患者及無慢性腎臟疾病者，共病及藥物使用情況。本研究利用邏輯斯回歸分析方法，預測使用降血壓或降血脂藥物後造成慢性腎臟疾病的風險大小。
研究結果：患有高血壓的男性罹患慢性腎臟疾病的OR=2.11、女性OR=2.36；患有糖尿病的男性OR=1.22、女性OR=1.41；患有痛風的男性OR=1.41、女性OR=1.28；患有胃潰瘍的男性OR=1.24、女性OR=1.32；患有酸鹼平衡異常的男性OR=2.35、女性OR=2.29，而心房纖維性顫動只有在男性看到顯著性差異，其OR=1.47。依使用率高之降血壓藥，血管收縮素受體阻斷劑(Angiotensin II receptor antagonist，ARB)類中，使用Valsartan的男性OR=0.44、女性OR=0.29；使用Losartan potassium的男性OR=1.40、女性OR=0.55；使用Irbesartan的男性OR=1.29、女性OR=1.26，而甲型交感神經阻斷劑(α-adrenergic antagonists)類中，使用Terazosin的男性OR=0.63、女性OR=3.81；使用Doxazosin (METHANESULFONATE)的男性OR=0.75、女性OR=2.35；使用Doxazosin (MESYLATE)的男性OR=0.86、女性OR=6.79，另外血管收縮素轉換酶抑制(Angiotensin-I converting enzyme inhibitors，ACEI)類中，使用Enalapril的男性OR=3.54、女性OR=2.49。依使用率較高之降血脂藥物，HMG-CoA還原酶抑制劑(3-hydroxy-3-methyl- glutaryl-coenzyme A reductase inhibitor，statin)類中，使用Atorvastatin男性OR=0.40、女性OR=0.36，使用Simvastatin男性OR=0.79、女性OR=0.84，使用Lovastatin男性OR=1.53、女性OR=0.75，使用Fluvastatin sodium男性OR=4.19、女性OR=2.29，使用Pravastatin sodium男性OR=2.59、女性OR=2.42，而Fibrate類，使用Gemfibrozil男性OR=0.92、女性OR=0.68，使用Fenofibrate男性OR=2.20、女性OR=2.07。
結論：在老年人中對於腎臟功能具保護效益上，降血壓藥和降血脂藥分別以Valsartan和Atorvastatin為優先選擇的治療藥物。降血壓藥，以Valsartan對腎臟最具保護性；以Enalapril及Hyderalazine hcl對慢性腎臟疾病罹患的風險性最高。降血脂藥，以Atorvastatin對腎臟最具保護性；以Fluvastatin、Pravastatin及Fenofibrate對慢性腎臟疾病罹患的風險性最高。

關鍵字

慢性腎臟疾病 ； 降血壓藥 ； 降血脂藥

並列摘要

Purpose：The purpose of this study was to explore the association between utilization of Anti-hypertensive drugs or Anti-hyperlipidemic drugs and chronic kidney disease (CKD) in elderly.
Method：A retrospective cohort study method was used in this study,the database is composed of 320,000 subjects whom were randomly selected from National Health Insurance (NHI) Research Database,the study participations were 60 years old and more in Taiwan from 2000 to 2009.To compare the comorbidity and drug use between CKD and non-CKD,we conducted the logistic models to predict the odds ratio of Anti-hypertensive drugs or Anti-hyperlipidemic drugs cause CKD.
Results：After adjusted for the other comorbidity covariables,multivariate logistic model showed the odds ratio for hypertension 【OR=2.11 for male and OR=2.36 for female】and diabetes mellitus【OR=1.22 for male and OR=1.41 for female】and gout【OR=1.41 for male and OR=1.28 for female】and Gastric ulcer【OR=1.24 for male and OR=1.32 for female】and abnormal acid-base balance【OR=1.32 for male and OR=2.29 for female,but there was only significant for male Atrial fibrillation 【OR=1.47】not female. After adjusted other drugs covariables,multivariate logistic model showed CKD was associated with hypotensive drugs utilization of Valsartan【OR=0.44 for male and OR=0.29 for female】,Losartan potassium【OR=1.40 for male and OR=0.55 for female】,Irbesartan【OR=1.29 for male and OR=1.26 for female】,Terazosin【OR=0.63 for male and OR=3.81 for female】,Doxazosin (METHANESULFONATE) 【OR=0.75 for male and OR=2.35 for female】, Doxazosin (MESYLATE)【OR=0.86 for male and OR=6.79 for female】,and Enalapril【OR=3.54 for male and OR=2.49 for female】;and Anti- hyperlipidemic drugs utilization of Atorvastatin【OR=0.40 for male and OR=0.36 for female】,Simvastatin【OR=0.79 for male and OR=0.84 for female】,Lovastatin【OR=1.53 for male and OR=0.75 for female】,Fluvastatin sodium【OR=4.19 for male and OR=2.29 for female】,Pravastatin sodium 【OR=2.59 for male and OR=2.42 for female】,Gemfibrozil【OR=2.59 for male and OR=2.42 for female】,and Fenofibrate【OR=2.20 for male and OR=2.07 for female】.
Conclusion：Our findings suggested that Valsartan and Atorvastatin could be a better choice of the medical treatment for the elderly and to protection efficiency of kidney function.
The results of this study also found that Enalapril and Hyderalazine hcl are higher risk for their kidney function in the Anti-hypertensive drugs. Additionally，Fluvastatin、Pravastatin、Fenofibrate are higher risk for their kidney function in the Anti-hyperlipidemic drugs.
Keywords：Chronic kidney disease、Anti-hypertensive drugs、 Anti-hyperlipidemic drugs

並列關鍵字

Chronic kidney disease ； Anti-hypertensive drugs ； Anti-hyperlipidemic drugs

參考文獻

2.台灣腎臟醫學會. 行政院衛生署國民健康局 慢性腎臟病防治手冊. 中華民國99年12月.

9.吳希文, 史麗珠, 張睿詒,等. 慢性腎臟病與其相關因子之探討－以社區成人健康檢查資料分析. 臺灣公共衛生雜誌 2009;28(5):374-84.

14.廖振凱、陳雅吟、賴銘南、游明謙. 誤用馬兜鈴科植物為中藥材之省思. J Chin Med 100年09月13日.

1.Bansal N, Hsu CY. Long-term outcomes of patients with chronic kidney disease. Nature clinical practice Nephrology 2008;4(10):532-3.

3.Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371(9631):2173-82.